Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

AD-RIDDLE Real-world Implementation, Deployment and Validation of Early Detection Tools and Lifestyle Enhancement

Coordinator
Region Stockholm, Sweden
Runs
1 January 2024 to 31 December 2028
Status
Running
EU funding
€12.1m
Total cost
€29.1m
Partners
28 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101132933

What the project is doing

In the project's own words, from its summary on CORDIS.

Alzheimer's disease (AD), the main cause of dementia, is one of the major global health challenges of our time. This disabling disorder affects 55 million people worldwide, with costs above $1.3 trillion. With 67 million people at risk for AD dementia (prodromal and preclinical AD) in Europe alone, it is a major unmet public health need, with increasing burden for European economies, healthcare and social care systems and a concern for the future.

Yet, prevention and early detection strategies have been lacking. Recent advances in disease-modifying therapies and the huge potential benefits of preventive multidomain interventions based on modifiable lifestyle and vascular factors (prevention potential ~ 40%) provide new opportunities. New developments in blood-based biomarkers (BBMs) and digital cognitive tests enable broader, cost-effective testing. The AD-RIDDLE platform is envisioned to revolutionize how AD is detected and diagnosed, prevented and treated across healthcare settings (HCS).

AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable HCS and practitioners to deploy enhanced AD management across diverse patient populations. The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and BBMs, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach.

The toolbox usability and efficacy with be tested in real-world settings. We expect that the AD-RIDDLE modular and flexible design can facilitate broad uptake from different healthcare systems, and its tools can advance research to develop cost-effective preventive therapies for AD, with scalability for other dementias

Who is involved

OrganisationCityCountryRole
Region StockholmStockholmSwedenCoordinator
Fujirebio Europe NVZwijnaarde GentBelgiumParticipant
Davos Alzheimer's CollaborativeGeneveSwitzerlandParticipant
Neotiv GmbHMagdeburgGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyAssociatedpartner
Fundacio Barcelonabeta Brain Research CenterBarcelonaSpainParticipant
Synapse Research Management Partners SLMadridSpainParticipant
Combinostics OyTampereFinlandParticipant
Ita-Suomen YliopistoKuopioFinlandParticipant
Sanofi-Aventis Recherche & DeveloppementGentillyFranceParticipant
Universita Degli Studi Di PerugiaPerugiaItalyParticipant
Alzheimer EuropeSenningerbergLuxembourgParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Goeteborgs UniversitetGoeteborgSwedenParticipant
Karolinska InstitutetStockholmSwedenParticipant
Lunds UniversitetLundSwedenParticipant
Stiftelsen Fingers Brain Health InstituteSolnaSwedenParticipant
Vastra GotalandsregionenVanersborgSwedenParticipant
Cambridge Cognition LimitedCambridgeUnited KingdomParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomAssociatedpartner
National Institute for Health and Care ExcellenceManchesterUnited KingdomAssociatedpartner
University of LeicesterLeicesterUnited KingdomAssociatedpartner
Alzheimer's Disease International the International Federation of Alzheimer's Disease and Related Disorders Societies IncLincolnshireUnited StatesParticipant
C2n Diagnostics LlcSt LouisUnited StatesParticipant
Davos Alzheimer's CollaborativeWaye PaUnited StatesParticipant
Gates Ventures LlcKirklandUnited StatesParticipant
Sanofi US Services Inc.Cambridge, MassachusettsUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI